Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5... | December 27, 2022

Related Keywords

China ,Ying Luo ,Liaoning ,Beijing ,Japan ,Tokyo ,United States ,Canada ,Chinese ,Trisha Colton ,Nassim Usman ,Augustine Lawlor ,Raymond James ,Thomas Eastling ,Gibson ,Catalyst Biosciences Inc ,Nasdaq ,Group Ltd ,Group In Subsequent Transaction ,Dunn Crutcher ,Securities Exchange ,Company Or Catalyst ,Leadership Organization ,Globenewswire Inc ,Herrington Sutcliffe ,Pharma Company ,Acquire Controlling Interest ,Based Commercial Pharma Company ,Special Dividend ,Contingent Value Right ,Meeting Planned ,Host Conference Call Today ,Beijing Continent ,Mainland China ,Catalyst Board ,Chief Executive Officer ,Interim Chief Financial Officer ,Seriesx Preferred Stock ,Preferred Stock ,Business Combination ,Business Combination Agreement ,Catalyst Common Stock ,Securities Exchange Act ,Securities Act ,Minority Holders ,Annual Report ,Quarterly Reports ,Current Reports ,Additional Information Will ,Catalyst Biosciences ,Nc Stock Exchange ,News ,Information ,Press Release ,Cquires ,Hase , ,Drug ,O ,Treat ,Ibrosis ,Hill ,Cquire ,Controlling ,Interest ,N ,Commercial ,Dharma ,Rom ,The ,Dni ,Group ,Subsequent ,Transaction ,Nnounces Cbio Us14888d2080 ,